RT Journal Article
SR Electronic
T1 The variable genomic landscape during osteosarcoma progression: insights from a longitudinal WGS analysis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.04.18.24306025
DO 10.1101/2024.04.18.24306025
A1 Meijer, Debora M.
A1 Ruano, Dina
A1 Briaire-de Bruijn, Inge H.
A1 Wijers-Koster, Pauline M.
A1 van de Sande, Michiel A.J.
A1 Gelderblom, Hans
A1 Cleton-Jansen, Anne-Marie
A1 de Miranda, Noel F.C.C.
A1 Kuijjer, Marieke L.
A1 Bovée, Judith V.M.G.
YR 2024
UL http://medrxiv.org/content/early/2024/04/19/2024.04.18.24306025.abstract
AB Osteosarcoma is a primary bone tumor that exhibits a complex genome characterized by gross chromosomal abnormalities. Osteosarcoma patients often develop metastatic disease, resulting in limited therapeutic options and poor survival rates. To gain knowledge on the mechanisms underlying osteosarcoma heterogeneity and metastatic process, it is important to obtain a detailed profile of the genomic alterations that accompany osteosarcoma progression. We performed WGS on multiple tissue samples from six patients with osteosarcoma, including the treatment naïve biopsy of the primary tumor, resection of the primary tumor after neoadjuvant chemotherapy, local recurrence and distant metastases. SNVs and structural variants were found to accumulate over time, contributing to an increased complexity of the genome of osteosarcoma during progression. Phylogenetic trees based on SNVs and structural variants reveal distinct evolutionary patterns between patients, including linear, neutral and branched patterns. The majority of osteosarcomas showed variable copy number profiles or gained whole genome doubling in later occurrences. Additionally, chromothripsis is not confined to a single early event, as multiple other chromothripsis events may appear in later occurrences. Together, we provide a detailed analysis of the complex genome of osteosarcomas and show that five out of six osteosarcoma genomes are highly dynamic and variable during progression.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was financially supported by the intramural Leiden Center for Computational Oncology strategic fund. M.L.K.is funded by the Norwegian Research Council, Helse Sør-Øst and the University of Oslo through the Centre for Molecular Medicine Norway (grant no. 187615), the Norwegian Research Council (grant no. 313932), and the Norwegian Cancer Society (grant no. 214871 and 273592). N.F.C.C.d.M. is funded by the European Research Council (ERC) under the European Unions Horizon 2020 Research and Innovation Program (grant agreement no. 852832) and by the VIDI ZonMW (project number: 09150172110092).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Approval of institutional review board (Medisch-Ethische Toetsingscommissie Leiden Den Haag Delft) was obtained for the use of tissue samples from the LUMC bone and soft tissue tumor biobank (Leiden, the Netherlands) (B20.067). Written informed consent from patients was obtained. All specimens were pseudoanonymized and handled according to the ethical guidelines described in Code for Proper Secondary Use of Human Tissue in The Netherlands of the Dutch Federation of Medical Scientific Societies.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors